Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
It depends on the country. Overdiagnosis relates to the finding of a cancer that doesn’t act in a life-limiting way. Since the beginning of mammography and PSA eras we have diagnosed a lot of such disease.Mammography has not changed the percentage of women who have metastatic disease, rather it has ....
A benign tumor means it’s not cancer. These tumors don’t spread to other parts of the body and are usually not life-threatening. However, depending on their size or location, they may need to be removed if they press on important organs or cause discomfort.
Mammograms are performed today for two reasons: they help detect breast cancer and also help confirm a diagnosis if another screening option shows the presence of cancerous cells. Mammograms might be able to help screen for breast cancer in some cases, but they do nothing to help prevent or treat br....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
लेखक:Dr. Nitika Sharma - BDS
समीक्षा की गई:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.